Dr. Arun Menawat reports

PROFOUND MEDICAL REPORTS STRONG PRELIMINARY THIRD QUARTER 2026 REVENUE

Profound Medical Corp. has released preliminary unaudited revenues for the third quarter ended Sept. 30, 2026. Unless specified otherwise, all amounts in this news release are expressed in U.S. dollars.

Based on these preliminary results, the company expects to report record-breaking quarterly revenue that is above current Wall Street expectations.

Preliminary financial highlights:

• Total revenue: expected to be in the range of $9.8-million to $10.0-million;
• Year-over-year growth: expected to increase approximately 85 per cent to 89 per cent compared with $5.3-million in the third quarter of 2025;
• Sequential quarter-over-quarter growth: expected to increase approximately 292 per cent to 300 per cent compared with $2.5-million in the second quarter of 2026;
• Versus consensus: expected revenue is approximately 45 per cent to 47 per cnet above the Bloomberg mean analyst consensus of $6.78-million (1);
• Gross margin: Q3 (third quarter) 2026 gross margin is again expected to exceed 70 per cent, reflecting continued progress in the company's commercial operations and scale.

"The significant increase in revenue we expect to report this quarter represents a historic milestone for Profound, reflecting the strong commercial momentum building behind our technology," said Dr. Arun Menawat, Profound's chief executive officer and chairman. "The expected year-over-year and sequential growth in the third quarter reflects increased commercial activity across our installed base and new customer accounts."

Dr. Menawat continued: "With preliminary revenue of approximately $9.8-million to $10.0-million and gross margin expected to exceed 70 per cent, we believe the third quarter represents an important step in the continued expansion of our commercial business. We remain focused on supporting customer adoption, increasing utilization of our installed base and building a profitable growth company over the long term."

These figures are preliminary and unaudited, and actual revenues may differ. In addition, consensus estimates are based on the work of third party analysts, and the company does not endorse, adopt or control them. Profound intends to report full third quarter 2026 financial results after market close on Thursday, Nov. 5, 2026, and will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Third quarter 2026 results conference call details

Date:  Thursday, Nov. 5, 2026

Time:  4:30 p.m. ET

Live call registration:  on-line

The call will also be broadcast live and archived on the company's website in the investors section.

(1) As compared with the Bloomberg consensus estimate compiled as of Oct. 7, 2026, at 9:02 a.m. ET.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company's flagship platform, Tulsa-Pro, enables MRI-guided, incision-free prostate ablation. Physicians use the Tulsa Procedure to see, ablate and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care-from whole-gland to subtotal, hemi, multifocal and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side-effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumours and osteoid osteoma, as well as for common gynecologic conditions, including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay and faster recovery -- and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Profound Medical's technologies are approved across major global markets. Tulsa-Pro is cleared by the U.S. Food and Drug Administration (FDA) in the United States for transurethral ultrasound ablation (Tulsa) of prostate tissue. In addition, Tulsa-Pro is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the United Arab Emirates. Sonalleve is approved by the FDA as HDE in the United States for the treatment of osteoid osteomas in the extremities. Sonalleve is also cleared or approved in the Europe, Canada, China and Saudi Arabia.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy -- expanding access to precise, personalized and incision-free treatment options worldwide.

We seek Safe Harbor.